Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin plus BCG after TURBT in HER2-positive high-risk non-muscle invasive bladder cancer
ChiCTR2400080767Phase 2Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Feb 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and bcg vaccine in bladder cancer and transitional cell carcinoma (TCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 2-year recurrence-free survival. Started Feb 2024; status: completed.
02
Drugs
disitamab vedotinbcg vaccine
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2400080767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080767.